Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
772.700.06%
QQQ
717.030.09%
BTC/USD
80747.970.6498%
DIA
536.820.02%
GLD
410.870.16%
TLT
82.140.09%

Amylyx Pharmaceuticals Inc

AMLXNASDAQ
Trade with Public
Trade with Public
$33.96
-0.53-1.54%
At close: Sep 3, 5:00 PM EST
$33.99
0.030.09%
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Amylyx Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amylyx Pharmaceuticals (AMLX).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

10Buy
1Hold
Consensus RatingBuy# Analysts11Avg. Consensus PT$28Upside to Avg. PT-18.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 27, 2026GuggenheimSeamus FernandezPT RaiseBuy$55→$57
Aug 19, 2026MizuhoGraig SuvannavejhPT RaiseOutperform$30→$42
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $55 to $57.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $30 to $42.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $40 to $55.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

HC Wainwright & Co. analyst Andrew S. Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $34 to $55.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $24 to $30.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved